|
|
|
Insider
Information: |
Hanish Arnold C |
Relationship: |
Director |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
19,051 |
|
Indirect Shares
|
22,844 |
|
|
Direct
Value |
$12,918,718 |
|
|
Indirect Value
|
$6,341,036 |
|
|
Total
Shares |
41,895 |
|
|
Total
Value |
$19,259,754 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
0.0%
|
-48.2%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Eli Lilly & Co |
LLY |
Chief Accounting Officer |
2012-08-29 |
17,611 |
2012-08-29 |
8,590 |
Premium* |
|
Omeros Corp |
OMER |
|
2023-05-22 |
0 |
2023-05-22 |
12,400 |
Premium* |
|
Salarius Pharmaceuticals, Inc |
SLRX |
Director |
2023-01-03 |
1,440 |
2023-01-03 |
1,854 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
OMER |
Omeros Corp |
|
|
2023-05-22 |
4 |
S |
$6.46 |
$32,300 |
D/D |
(5,000) |
0 |
0 |
% |
|
OMER |
Omeros Corp |
|
|
2023-05-22 |
4 |
OE |
$5.30 |
$26,500 |
D/D |
5,000 |
5,000 |
0 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,440 |
1,440 |
0 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2022-06-03 |
4 |
B |
$0.18 |
$5,152 |
I/I |
28,000 |
46,350 |
2.1 |
- |
|
OMER |
Omeros Corp |
|
|
2021-09-08 |
4 |
OE |
$9.44 |
$94,400 |
I/I |
10,000 |
10,000 |
0 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2021-08-10 |
4 |
B |
$0.88 |
$6,167 |
I/I |
7,000 |
18,350 |
2.1 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2020-08-21 |
4/A |
B |
$0.98 |
$3,920 |
I/I |
4,000 |
11,350 |
2.1 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2020-08-21 |
4 |
B |
$0.98 |
$3,920 |
D/D |
4,000 |
11,350 |
2.31 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2020-02-11 |
4/A |
B |
$1.15 |
$5,003 |
I/I |
4,350 |
7,350 |
2.1 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2020-02-11 |
4 |
B |
$1.15 |
$5,003 |
D/D |
4,350 |
7,350 |
2.39 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2019-11-25 |
4/A |
B |
$3.59 |
$10,770 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2019-11-25 |
4/A |
B |
$3.59 |
$10,770 |
I/I |
3,000 |
3,000 |
2.1 |
- |
|
SLRX |
Salarius Pharmaceuticals,... |
Director |
|
2019-11-25 |
4 |
B |
$3.59 |
$10,770 |
D/D |
3,000 |
6,000 |
2.39 |
- |
|
OMER |
Omeros Corp |
Director |
|
2013-01-03 |
4 |
B |
$5.58 |
$11,160 |
D/D |
2,000 |
2,400 |
2.39 |
- |
|
OMER |
Omeros Corp |
Director |
|
2012-09-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
400 |
|
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2012-08-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
136 |
17,611 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2012-05-18 |
4 |
S |
$40.49 |
$52,435 |
D/D |
(1,295) |
17,747 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2012-05-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
238 |
19,042 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2011-05-17 |
4 |
S |
$39.12 |
$132,147 |
D/D |
(3,378) |
17,045 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2011-05-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
243 |
20,423 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2011-01-25 |
4 |
A |
$34.73 |
$118,603 |
D/D |
3,415 |
20,666 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2010-03-04 |
5 |
GD |
$0.00 |
$0 |
D/D |
232 |
17,251 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2010-01-26 |
4 |
A |
$36.16 |
$122,148 |
D/D |
3,378 |
17,483 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2009-11-20 |
4 |
S |
$36.65 |
$97,965 |
D/D |
(2,673) |
14,105 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Chief Accounting Officer |
|
2009-08-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
187 |
16,778 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|